{
    "clinical_study": {
        "@rank": "99406", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and anti-HBV activity of ACH-126, 443\n      (beta-L-Fd4C) in comparison to lamivudine or placebo in treatment naive adults with chronic\n      Hepatitis B infection."
        }, 
        "brief_title": "Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection", 
        "completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluation of safety and antiviral activity of 3 dose levels of ACH-126, 443 vs. lamivudine\n      and placebo over 12 weeks of treatment in the population described."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults >= 18 years of age\n\n          -  Chronic HBV infection, known to be HbsAg positive >= 6 months\n\n          -  Plasma HBV DNA level >= 100,000 copies/mL\n\n          -  HBe-antigen positive\n\n          -  HIV negative\n\n          -  Basic hematologic and chemistry parameters within acceptable limits (defined in\n             protocol\n\n          -  No need for excluded medications\n\n          -  Subjects of reproductive capability must utilize two approved forms of birth control,\n             one of which must be barrier protection.\n\n        Exclusion Criteria:\n\n          -  HIV infection\n\n          -  Hepatitis C co-infection\n\n          -  Concurrent systemic antiviral treatment\n\n          -  Previous antiviral treatment for HBV infection within 6 months prior to randomization\n             or treatment with 3TC for more than 6 months at any time in the past\n\n          -  Previous therapy with agents with significant systemic myelosuppressive or cytotoxic\n             potential within 3 months of study start or the expected need for such therapy at\n             study start\n\n          -  Alcohol abuse\n\n          -  Pregnancy or breast-feeding\n\n          -  Inability to tolerate oral medication\n\n          -  AST>7.0 times the upper limit of normal\n\n          -  ALT>7.0 times the upper limit of normal\n\n          -  Any clinical condition or prior therapy that, in the Investigators opinion, would\n             make the subject unsuitable for the study or unable to comply with the dosing\n             requirements\n\n          -  Use of any investigational drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "79", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 26, 2002", 
        "id_info": {
            "nct_id": "NCT00034359", 
            "org_study_id": "ACH443-003"
        }, 
        "intervention": [
            {
                "intervention_name": "ACH-126, 443 (beta-L-Fd4C)", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Lamivudine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "keyword": [
            "E-antigen positive", 
            "Treatment Naive Chronic Hepatitis B, Achillion"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "link": {
            "url": "http://www.achillion.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Clinic of Gastroenterology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Foundation of Gastroenterology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Former Yugoslavia"
                    }, 
                    "name": "Clinic Center of Serbia, Institute of Infectious Disease"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novi Sad", 
                        "country": "Former Yugoslavia"
                    }, 
                    "name": "Clinic of Novi Sad"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Former Yugoslavia"
            ]
        }, 
        "official_title": "A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults", 
        "overall_official": {
            "affiliation": "Achillion Pharmaceuticals", 
            "last_name": "Lisa M Dunkle, M.D."
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034359"
        }, 
        "source": "Achillion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Achillion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }, 
    "geocoordinates": {
        "Clinic Center of Serbia, Institute of Infectious Disease": "44.802 20.466", 
        "Clinic of Gastroenterology": "42.696 23.326", 
        "Clinic of Novi Sad": "45.25 19.85", 
        "Foundation of Gastroenterology": "42.696 23.326"
    }
}